智通财经APP获悉，华芢生物-B(02396)跌超12%，低见18.6港元再创上市新低，较招股价38.2港元已腰斩。截至发稿，跌11.77%，报18.67港元，成交额746.2万港元。
据悉，华芢生物是一家生物制药公司，专注于伤口愈合疗法的发现、开发与商业化。截至2025年12月5日，公司管线共布局十款候选产品，其中七款为PDGF候选药物，涵盖Pro-101-1和Pro-101-2两款核心产品。财务方面，目前公司尚未通过产品销售产生任何收入。2023年、2024年以及截至2025年9月30日，公司净亏损分别为1.1亿元、2.1亿元及1.3亿元。公司绝大多数的净亏损均来自研发费用及行政开支。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.